Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

Phase 1/2 Recruiting 415 enrolled Guangzhou Excelmab Inc.

NaSequentialOpen-labelTreatment

Summary

This is a multicenter, single-arm, open, dose-escalation Phase I/II clinical trial, consisting of a dose-escalation phase (accelerated titration phase, 3+3 design) and a dose expansion phase.

Timeline

Start: 2021-11-12
Primary completion: 2025-10
Completion: 2025-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EX103	Monoclonal antibody	—	—

Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

Summary

Timeline

Drugs

Indications